The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Leqvio Market Become By 2030 Compared To 2026?
Historically, this growth is primarily linked to the rising occurrence of hyperlipidemia, breakthroughs in RNA interference technology, the proliferation of cardiovascular specialty clinics, heightened understanding of LDL cholesterol management, and enhancements in injectable drug delivery systems.
The anticipated expansion during the projected timeframe stems from the wider acceptance of innovative RNA-based treatments, a heightened emphasis on mitigating cardiovascular risks, the proliferation of therapies requiring less frequent administration, escalating financial commitments to cardiometabolic studies, and a greater need for lasting solutions to reduce lipids.
Key developments expected during the forecast period encompass the growing embrace of siRNA-based treatments for lipid reduction, a surge in demand for cardiovascular therapies with extended effects, an intensified attention on proactive heart health interventions, the broadening of sophisticated RNA production methods, and an increased priority placed on improving patient compliance with treatments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp
What Key Growth Drivers Are Influencing The Leqvio Market?
The increasing number of older adults is anticipated to fuel the demand for leqvio in the future. This demographic comprises people generally aged 65 years and older. Significant progress in healthcare and medical technology has notably extended life expectancy, thus expanding the geriatric demographic. Leqvio helps reduce LDL cholesterol, simplifying medication routines for senior citizens. Its prolonged action diminishes cardiovascular hazards, thereby improving health results among the elderly. For example, data from January 2024, provided by the Population Reference Bureau, a Kenya-based nonprofit, indicates that the count of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Concurrently, this cohort’s proportion of the total population is forecast to increase from 17% to 23% within the same timeframe. Consequently, the expanding geriatric population is a key catalyst for the leqvio market’s expansion.
What Key Segment Areas Are Included In The Leqvio Market Assessment?
The leqvio market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors
2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia
3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers
Which Trends Are Affecting The Leqvio Market Framework?
Leading pharmaceutical firms are active in the Leqvio market, concentrating on the development of sophisticated injectable prescription drugs, utilizing strategies like Label Expansion to improve therapeutic access and facilitate earlier patient intervention. Label Expansion denotes the regulatory authorization provided by bodies like the FDA, permitting an existing approved medication to be utilized for new indications, different patient demographics, or in clinical contexts beyond its initial approval. As an illustration, in July 2023, the Swiss pharmaceutical company Novartis AG obtained approval from the US Food and Drug Administration (FDA) for an updated label for Leqvio (inclisiran). This update permits its administration at an earlier point for individuals with elevated LDL-C and a heightened risk of heart disease, alongside dietary changes and statin treatment. Administered with two doses per year following two initial doses, Leqvio achieves up to a 52% LDL-C reduction and has demonstrated efficacy for patients who cannot achieve their LDL-C goals even with statin therapy. The revised label emphasizes strong safety and effectiveness data, which was further substantiated by the VictORION clinical trial program.
Which Companies Are Influencing The Leqvio Market?
Major companies operating in the leqvio market are Novartis AG
Access The Complete Leqvio Market Report:
https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report
Which Region Stands As The Largest Contributor To The Leqvio Market?
North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model